Surrozen (SRZN) Cash from Operations (QoQ) (2021 - 2026)
Surrozen (SRZN) Cash from Operations (QoQ) (2021 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Alterity Therapeutics |
719,706.53 Bn |
719,706.50 Bn |
- |
| 2 |
Belite Bio |
55,800.00 Bn |
55,800.00 Bn |
- |
| 3 |
Quantum Biopharma |
18,182.30 Bn |
18,182.29 Bn |
- |
| 4 |
Legend Biotech |
3,154.00 Bn |
3,153.71 Bn |
242.10 Mn |
| 5 |
Akari Therapeutics |
1,844.30 Bn |
1,844.29 Bn |
- |
| 6 |
Evaxion A |
1,567.96 Bn |
1,567.94 Bn |
- |
| 7 |
Psyence Biomedical |
251.43 Bn |
251.42 Bn |
- |
| 8 |
Vertex Pharmaceuticals |
112.56 Bn |
105.31 Bn |
2.59 Bn |
| 9 |
Abivax |
94.37 Bn |
94.37 Bn |
- |
| 10 |
Surrozen |
225,877.86 |
-106.68 Mn |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
-113.81% |
| Dec 31, 2025 |
35.07% |
| Sep 30, 2025 |
-47.54% |
| Jun 30, 2025 |
34.41% |
| Mar 31, 2025 |
-365.03% |
| Dec 31, 2024 |
151.97% |
| Sep 30, 2024 |
-19.36% |
| Jun 30, 2024 |
34.98% |
| Mar 31, 2024 |
-19.18% |
| Dec 31, 2023 |
28.30% |
| Sep 30, 2023 |
-16.37% |
| Jun 30, 2023 |
38.26% |
| Mar 31, 2023 |
-8,756.25% |
| Dec 31, 2022 |
98.87% |
| Sep 30, 2022 |
-24.29% |
| Jun 30, 2022 |
38.11% |
| Mar 31, 2022 |
-59.58% |
| Dec 31, 2021 |
17.98% |
| Sep 30, 2021 |
-9.15% |
| Jun 30, 2021 |
-24.66% |
